Navigation Links
PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Date:4/2/2008

BOSTON, April 2, 2008 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company's international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL's Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.

"Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process," said Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "We expect that the extensive medical and scientific expertise Dr. Ereshefsky and Dr. Bajbouj bring to our clinical pharmacology business will further strengthen our central nervous system capabilities in order to help biopharmaceutical companies address growing complexity in this important area of early phase clinical development."

Dr. Larry Ereshefsky is Board Certified in Psychiatric Pharmacy, and has more than 28 years of experience in the neuropsychopharmacology and psychiatry fields. His expertise includes all phases of clinical research and psychopharmacological ev
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
2. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
4. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
5. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
6. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
7. PAREXEL International Announces 2-For-1 Stock Split
8. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The FBI recently approved the Promega P...icipating in or generating DNA records for the Nat... Madison, WI USA (PRWEB) -- The FBI recently appro...use by laboratories participating in, or generatin...NDIS). NDIS currently contains more than seven mil...
(Date:11/24/2009)...URE:HTL , TORONTO,Nov.24/PRNewswire-FirstCall...italInc.,aleadingproviderofadvancedlasersystemsand...cmarkets,todayreportedoperationalandfinancialresul...009Highlights,-Revenuewas$1.46millioncomparedwith...entcomparedwith66.1percentinQ3,2008,-Netlossreduce...
(Date:11/24/2009)...O,Nov.24,2009/PRNewswire-FirstCall/--ArenaPharmace...companyisscheduledtopresentatthePiperJaffray21stAn....EasternTime(8:30a.m.PacificTime)attheNewYorkPalac...ChiefExecutiveOfficer,isscheduledtoprovideanovervi...iscoveryprograms. ,, Aliveaudiowebcastofthepres...
(Date:11/24/2009)...taly,November24/PRNewswire/--HealthRoboticstodayan...hagroupofselected,investors.ThisrecentlyformedToro...ticsCanada,Inc.andwillmarket,install,andsupport,He...desthe,revolutionaryproductofferingsi.v.STATION(TM....willalsoprovideassistanceonan"asneeded,basis"toit...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...: SHP,NASDAQ: SHPGY ), the global specialty biop...ion agreement with GlaxoSmithKline plc (NYSE: GS...apsules CII with the aim of,improving recognition ...greement covers the United States and will more th...ales effort for VYVANSE by adding over 600 sales,r...
...eted product, a new vaccine against Japanese Encep... - Commercial product launch in the U.S. planned f...E: ICLL) today announced that the U.S. Food and Dr...vaccine for the prevention of Japanese Encephaliti...vaccine - the only such product currently manufact...
...nsulting US, a division of London-based Double Hel...ent of Ann Stuchiner to the position of Vice Presi... highly experienced strategic pricing, reimburseme...perience across the healthcare industry, which pro...n the pharmaceutical, biotechnology and medical de...
Other Biology Technology:Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife Con...evealing that the last remaining population of Sib... to the rising tide of poaching and habitat loss. ...rm Russian officials of what needs to be done to p...t cat. , The report was released by...
(Date:11/24/2009)... (November 24, 2009) New research on bacterial co...tems reveals predictable temporal patterns, sugges...s markers for monitoring climate change in the pol... Proceedings of the National Academy of Sciences ... the six rivers shifted synchronously over time, c...
(Date:11/23/2009)...C. The community-associated strain of the deadly ...nt to most common antibioticsposes a far greater h...ts way into hospitals, according to a study in the... , The new threat is easily picked up in fitnes...s increased the overall burden of MRSA within hosp...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 1Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 2GENova appoints Director of Asian business development 56661 1GENova appoints Director of Asian business development 56661 2Vita Tech International Inc Donates One Ton of Vitamins To Polio Treatment Centers in Guinea West Africa 13950 1
...ns School of Medicine and their colleagues have fo...ptor in addition to their own can acquire new colo... rapidly to new sensory information than anticipat...lso suggests that when the first ancestral primate...0 million years ago, it probably experienced immed...
...School of Medicine & Dentistry at The Universi...Edinburgh, have discovered a way to kill the cysti...se investigators, under the leadership of Dr. Migu...ogy, have had their research published in the May ...ted in Nature Reviews/Microbiology. , B. cenocepa...
...pment of new neurons in specific brain regions aff...n, new research shows. How these new neurons stor...how they can affect learning and memory in adults...., of the Salk Institute, found that experience enh...called the dentate gyrus, and that more of these n...
Other Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Key found to kill cystic fibrosis superbug 2Experience affects new neuron survival in adult brain; study sheds light on learning, memory 2
RNA 6000 Nano Chip Kit from Agilent Technologies
Mouse Anti-Human ALPK3 Monoclonal Antibody, Unconjugated, Clone 4G4 from Abnova Corporation
...Lines ,High Quality, Functionally-Validated, Ion C...or having a critical role in nerve and muscle func... CNS and the heart. Drugs that modulate ion channe...ch as neuropathic pain, cardiac arrhythmia, hypert...
Mouse Anti-Human CD320 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: